VTGN News and Press, VistaGen Therapeutics Inc. From 11/12/20

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the Second Quarter of 2021 Received Over $17.5 Million Net Pr...

VistaGen Therapeutics (VTGN) announces new in vitro electrophysiology data demonstrating that the mechanism of action of PH94B, the intranasal neuroactive steroid in development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder ((SAD)), does not invo...

VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines New electrophysiological data demonstrate that PH94B does not directly modulate GABA (gamma aminobutyric acid) receptors PR Newswire SOUTH SAN FRANCIS...

VistaGen Therapeutics to Participate in the Guggenheim Healthcare Talks | Idea Forum | 2nd Annual Neuro/Immunology Day PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 SOUTH SAN FRANCISCO, Calif. , Nov. 9, 2020 /PRNewswire/ -- VistaGen Therapeutics (...

LOS ANGELES, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of...

Vistagen Therapeutics ([[VTGN]] +4.5%) received a notification letter from Nasdaq granting 180-day extension to regain compliance with Nasdaq's minimum bid price requirement.The Company now time until April 12, 2021 to meet the requirement."We believe we will regain c...

Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 SOUTH SAN FRANCISCO, Calif. , Oct. 14, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical com...

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, recently announced positive new data from the company's second preclinical study of its oral investiga...

SOUTH SAN FRANCISCO, Calif. , Sept. 3, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression, and other central nervous system (CNS) disorders, today announced positive new data from t...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...